MF

Max Farina

Principal at 5AM Ventures

San Francisco Bay Area

Overview 

Max Farina is a Life Science Investor at 5AM Ventures in the San Francisco Bay Area, with a background in biotechnology and extensive experience in financial modeling and team leadership. He holds a Doctor of Medicine from Yale School of Medicine and a Master of Business Administration from Yale School of Management. Max has made significant contributions in the field of life sciences, serving as a Principal at 5AM Ventures and holding board observer roles in multiple innovative companies, showcasing his expertise in evaluating and supporting emerging biotech ventures.

Work Experience 

  • Principal

    2024 - Current

  • Senior Associate

    2023 - 2024

  • Associate

    2021 - 2023

5AM Ventures is a venture capital firm that aims to finance seed and early-stage life sciences companies.

  • Board Observer

    2024

  • Board Observer

    2023

Portal Instruments is an early stage company that offers medical device.

Raised $48,999,998.00 from Takeda Ventures.

  • Board Observer

    2023

  • Board Observer

    2022

Fellow provides peer-reviewed, clinical semen analysis solutions that patients can conveniently perform at home.

  • Board Observer

    2022

TMRW Life Sciences provides an integrated platform for automated, software-guided cryospecimen management.

Raised $181,672,940.00 from 5AM Ventures, FIOS Venture Holdings, What If Ventures, Transformation Capital, LSI (Life Science Innovations Fund), Google Ventures, Casdin Capital and Amy Schumer.

  • Board Observer

    2021

Precede Biosciences is breaking down the barriers to precision medicine by redefining what can be gleaned from a simple blood draw.

Raised $57,000,000.00 from Illumina Ventures, OUP (Osage University Partners), Bristol-Myers Squibb, Lilly Asia Ventures, Qatar Investment Authority, Binney Street Capital and 5AM Ventures.

  • Board Observer

    2021

Kinaset Therapeutics is a biopharma company that focuses on advancement of novel drugs in areas of unmet medical needs.

Raised $41,500,000.00 from Gimv, Atlas Venture and 5AM Ventures.

  • Board Observer

    2021

  • Board Observer

    2021 - 2021

Entrada Therapeutics is a developer of novel therapeutics intended to treat devastating diseases.

Raised $301,599,999.00 from Janus Henderson Investors.

Articles About Max

Relevant Websites